LRMR logo

Larimar Therapeutics, Inc. Stock Price

NasdaqGM:LRMR Community·US$417.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

LRMR Share Price Performance

US$3.83
0.19 (5.22%)
US$3.83
0.19 (5.22%)
Price US$3.83

LRMR Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

3 Risks
1 Reward

Larimar Therapeutics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$166.0m

Other Expenses

-US$166.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-1.59
0%
0%
0%
View Full Analysis

About LRMR

Founded
n/a
Employees
71
CEO
Carole Ben-Maimon
WebsiteView website
www.larimartx.com

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Recent LRMR News & Updates

Recent updates

No updates